Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

Alessandro Serretti, Alberto Chiesa, Stefano Porcelli, Changsu Han, Ashwin A. Patkar, Soo Jung Lee, Moon Ho Park, Chi Un Pae

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalPsychiatry Research
Volume189
Issue number1
DOIs
Publication statusPublished - 2011 Aug 30

Fingerprint

Tryptophan Hydroxylase
Bipolar Disorder
Schizophrenia
Depression
Genes
Single Nucleotide Polymorphism
Therapeutics
Haplotypes
Antidepressive Agents
Antipsychotic Agents

Keywords

  • Bipolar disorder
  • Major depression
  • Schizophrenia
  • Tryptophan hydroxylase 2

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. / Serretti, Alessandro; Chiesa, Alberto; Porcelli, Stefano; Han, Changsu; Patkar, Ashwin A.; Lee, Soo Jung; Park, Moon Ho; Pae, Chi Un.

In: Psychiatry Research, Vol. 189, No. 1, 30.08.2011, p. 26-32.

Research output: Contribution to journalArticle

Serretti, Alessandro ; Chiesa, Alberto ; Porcelli, Stefano ; Han, Changsu ; Patkar, Ashwin A. ; Lee, Soo Jung ; Park, Moon Ho ; Pae, Chi Un. / Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. In: Psychiatry Research. 2011 ; Vol. 189, No. 1. pp. 26-32.
@article{bd1cea4a7cd84dd89ba124d9f4fb85ba,
title = "Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia",
abstract = "The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-{\AA}sberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.",
keywords = "Bipolar disorder, Major depression, Schizophrenia, Tryptophan hydroxylase 2",
author = "Alessandro Serretti and Alberto Chiesa and Stefano Porcelli and Changsu Han and Patkar, {Ashwin A.} and Lee, {Soo Jung} and Park, {Moon Ho} and Pae, {Chi Un}",
year = "2011",
month = "8",
day = "30",
doi = "10.1016/j.psychres.2011.02.001",
language = "English",
volume = "189",
pages = "26--32",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia

AU - Serretti, Alessandro

AU - Chiesa, Alberto

AU - Porcelli, Stefano

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Lee, Soo Jung

AU - Park, Moon Ho

AU - Pae, Chi Un

PY - 2011/8/30

Y1 - 2011/8/30

N2 - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

AB - The present study is aimed at exploring whether some single nucleotide polymorphisms (SNPs) within the tryptophan hydroxylase 2 gene (TPH2) could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia and whether they could predict clinical outcomes in Korean in-patients treated with antidepressants, mood stabilizers and antipsychotics, respectively. One hundred forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for six TPH2 SNPs (rs4570625, rs10748185, rs11179027, rs1386498, rs4469933, and rs17110747). Baseline and final clinical measures, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale and Positive and Negative Syndrome Scale, for patients with MD, BD and schizophrenia, respectively were recorded. None of the SNPs under investigation were associated with MD, BD and schizophrenia. However, in patients with MD, the rs4570625-rs10748185 G-A haplotype was significantly associated with higher endpoint MADRS severity, though not with response. Our results suggest that TPH2 variants neither have a major role in MD, BD and schizophrenia nor in response to treatments.

KW - Bipolar disorder

KW - Major depression

KW - Schizophrenia

KW - Tryptophan hydroxylase 2

UR - http://www.scopus.com/inward/record.url?scp=80051690979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051690979&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2011.02.001

DO - 10.1016/j.psychres.2011.02.001

M3 - Article

C2 - 21396719

AN - SCOPUS:80051690979

VL - 189

SP - 26

EP - 32

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -